Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Hikma continues to make strategic progress, positioning the business for future growth through new product launches, continued investment in R&D, and new strategic partnerships and acquisitions, which are all driving our ability to put better health within reach, every day. Our acquisition of Custopharm, which closed last week, enhances our R&D capabilities and pipeline while further expanding our portfolio of differentiated injectable medicines. More broadly across…